
Topic
FDA Approval
NDA, BLA, ANDA, 505(b)(2), label language, review packages, and approval-pathway interpretation.

Pricing & Access· May 31, 2026 · 12 min read

Pricing & Access· May 31, 2026 · 14 min read
Switching from compounded GLP-1s to FDA-approved therapy
By Ran Chen#GLP-1#FDA Approval#Market Access

Pipeline· May 31, 2026 · 10 min read
Olezarsen Tryngolza sNDA preview for severe hypertriglyceridemia
By Ran Chen#PDUFA Date#FDA Approval#Clinical Evidence

Pipeline· May 31, 2026 · 8 min read
Tebipenem HBr PDUFA preview for oral carbapenem access
By Ran Chen#PDUFA Date#FDA Approval#Infectious Disease

Pipeline· May 31, 2026 · 10 min read
Veligrotug vs Tepezza thyroid eye disease access guide
By Ran Chen#PDUFA Date#FDA Approval#Ophthalmology

Approvals· May 28, 2026 · 7 min read
Baxfendy coverage guide: baxdrostat access for uncontrolled hypertension
By Ran Chen#Hypertension#Cardiovascular#FDA Approval

Approvals· May 28, 2026 · 7 min read
Beqalzi coverage guide: sonrotoclax access in mantle cell lymphoma

Approvals· May 28, 2026 · 7 min read
Decnupaz coverage guide: pivekimab sunirine access in BPDCN

Pipeline· May 27, 2026 · 7 min read
ASCO 2026 pipeline evidence preview for formulary and access teams

Pricing & Access· May 27, 2026 · 7 min read